Fortis Life Sciences, LLC (“Fortis”) has acquired Toronto-based International Point of Care, Inc. (“IPOC”). IPOC develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. IPOC’s recently expanded 36,000 sq. ft. facility is Fortis’ third GMP and ISO 13485 compliant manufacturing site in North America.
Read the full article: Fortis Life Sciences Acquires International Point of Care //
Source: https://www.businesswire.com/news/home/20230712942946/en/Fortis-Life-Sciences-acquires-International-Point-of-Care